
Kymera Therapeutics (KYMR) Stock Forecast & Price Target
Kymera Therapeutics (KYMR) Analyst Ratings
Bulls say
Kymera Therapeutics is attractive because its targeted protein degradation platform is producing unusually strong early clinical validation across multiple programs, with KT-621 showing biologics-like efficacy in atopic dermatitis and KT-579 delivering >90% IRF5 degradation plus robust downstream biomarker inhibition. The company’s differentiated strategy is supported by clean safety signals, strong mechanistic rationale against historically hard-to-drug targets like STAT6 and IRF5, and a meaningful market opportunity in large autoimmune and immunology indications where oral alternatives could expand treatment uptake. The presence of a partnered IRAK4 program, continued pipeline expansion, and cash runway into 2029 further strengthen the fundamental case by reducing execution risk while preserving multiple near- and medium-term catalysts.
Bears say
Kymera Therapeutics is viewed negatively because its lead programs face substantial clinical and competitive risk, especially if KT-621 fails to show compelling efficacy versus key atopic dermatitis and asthma rivals in Ph2 BROADEN. The company also faces uncertainty from a novel degrader modality, where longer dosing could reveal prohibitive toxicity, compensatory signaling, or other safety issues not yet evident in early studies. Fundamentally, the outlook is pressured by the possibility that promising preclinical and early clinical signals will not translate into durable physician and patient enthusiasm, while regulatory, competitive, and pricing risks remain elevated, including pricing reform in the orphan space.
This aggregate rating is based on analysts' research of Kymera Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Kymera Therapeutics (KYMR) Analyst Forecast & Price Prediction
Start investing in Kymera Therapeutics (KYMR)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Kymera Therapeutics (KYMR) Forecast
Kymera Therapeutics (KYMR) Analyst Forecast & Price Prediction
Start investing in Kymera Therapeutics (KYMR)
Order type
Buy in
Order amount
Est. shares
0 shares